Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : THE WHITE HOUSE -- Ignore unavailable to you. Want to Upgrade?

To: GROUND ZERO™ who wrote (8809)	9/19/2007 9:48:37 PM
From: Gersh Avery	Read Replies (1) \| Respond to of 25737

from National NORML.. A forthcoming review in the British Journal of Pharmacology emphasizes the anti-inflammatory and neuroprotective effects of cannabinoids as they pertain to Alzheimer's disease. AD is among the family of neurodegenerative diseases -- like ALS, MS, and Parkinson's -- that some investigators believe may be modified by cannabis. As noted by the authors, "Cannabinoids offer a multi-faceted approach for the treatment of Alzheimer's disease by providing neuroprotection and reducing neuroinflammation, whilst simultaneously supporting the brain's intrinsic repair mechanisms by augmenting neurotrophin expression and enhancing neurogenesis." Quite an endorsement, with therapeutic implications that extend far beyond AD. Regards, -- Paul Armentano Senior Policy Analyst NORML \| NORML Foundation paul@norml.org 925-930-7327 (land) 703-606-7539 (cell)